Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Discover the hidden triggers of idiopathic pulmonary fibrosis (IPF) in your home. Learn to minimize risks from scents, cleaning products, allergens, GERD, and infections.

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Please provide your email address to receive an email when new articles are posted on . Disease progression occurred in more patients receiving placebo vs. an oral lysophosphatidic acid receptor 1 ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...

Project Leader: Steven Duncan, M.D. Idiopathic pulmonary fibrosis (IPF) is a morbid fibroproliferative lung disease of older adults that causes progressive dyspnea and hypoxemia. Current treatments ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...